Clinical trials exist to generate evidence that is reliable, reproducible, and safe. Every data point collected, every adverse event recorded, every consent conversation held sits within a chain of decisions made by people. Those people are your team. Their behaviour in practice is the direct product of how well they were trained.
ICH E6 (R3), the current Good Clinical Practice guideline, makes this explicit. The 2023 revision moves beyond procedural compliance and places a risk-based, proportionate approach at the centre of trial conduct. Section 2 of the guideline identifies sponsor and investigator responsibilities in relation to training as a foundational quality requirement. It is not optional. It is not a box to check at site initiation. It is a continuous obligation tied directly to trial integrity and, more importantly, to patient safety.
GCP training is not a regulatory formality. It is the mechanism by which every member of your trial team understands why their actions matter.
When a site coordinator documents a protocol deviation late or fails to report an adverse event within the required window, the root cause is rarely malicious intent. It is a gap between what the person understands and what the protocol demands. Training closes that gap or, when poorly executed, leaves it wide open.
The 2016 FDA analysis of clinical investigator inspection findings identified inadequate informed consent and protocol non-compliance as two of the most frequently cited deficiencies. Both are training failures before they are compliance failures. ICH E6 (R3) responds to precisely this pattern by requiring that training be role-specific, documented, and proportionate to the complexity and risk of the trial.
Consider what happens when a site team does not fully understand the safety reporting requirements in a complex oncology trial. An investigator flags a grade 2 adverse event but does not recognise it as meeting the threshold for expedited reporting under the protocol definition. The sponsor’s pharmacovigilance team does not receive the signal in time. A pattern that may have indicated a serious drug-related risk goes undetected for weeks.
This scenario reflects real inspection findings and real sponsor corrective action plans. The ICH E6 (R3) guideline addresses this directly by requiring that the sponsor ensure investigators are qualified by training and experience, and that sponsors themselves maintain oversight processes that confirm ongoing competency, not just initial qualification.
Your training programme must therefore answer a specific question: does every person on this trial, at every site, understand what to do when something goes wrong?
TRI GCP e-learning gives your team the scenario-based practice to answer yes with confidence.
Most sponsors and CROs design onboarding training. Far fewer design sustained competency. The distinction matters because knowledge fades, teams turn over, and protocols change.
ICH E6 (R3) introduces a clearer expectation around quality management systems and risk identification. This means training must be integrated into the trial’s risk framework, not treated as a standalone activity that precedes it. When you conduct a risk assessment at the protocol design stage, training gaps should appear as a category of operational risk alongside data integrity, subject recruitment, and site capability.
Common failure points include:
Each of these creates a point of vulnerability that reaches directly to the patient. If any of these gaps apply to your trial teams, our GCP e-learning is designed to close them.
ICH E6 (R3) Section 5 sets out sponsor responsibilities with renewed clarity on oversight and quality. The guideline shifts the framing from document-heavy compliance to risk-proportionate assurance. For training, this means you need to demonstrate not just that training occurred, but that it was appropriate to the role, adequate to the risk, and effective in practice.
Practically, this requires you to:
One of the clearest messages in ICH E6 (R3) is that sponsor accountability cannot be fully delegated. When a sponsor transfers responsibilities to a CRO, the sponsor retains oversight responsibility for the quality of those activities. This includes training.
If your CRO delivers site training on your behalf, you are responsible for the quality standard of that training. Your agreements with the CRO should specify training requirements, competency standards, and the evidence you expect to receive. Your oversight activities should include review of training records and, where risk warrants it, direct confirmation that training translated into competent practice.
This is not about distrust of your CRO. It is about recognising that the regulatory and ethical accountability for trial conduct sits with the sponsor, and that delegation without oversight creates exactly the kind of quality gap that ICH E6 (R3) was designed to address.
The clinical trials industry has invested heavily in learning management systems and e-learning modules. The infrastructure is there. The gap is often in how training is designed.
Training that changes behaviour connects regulatory requirements to real consequences. It uses case studies drawn from actual inspection findings. It asks staff to apply knowledge to scenarios they will genuinely encounter, not just recall definitions they may forget within days of completing a module.
The FDA’s published warning letters and the EMA’s inspection outcome reports are a resource your training team should use regularly. They document the precise points at which training failures translate into patient risk and data unreliability. Using these in your training design gives your team a direct line of sight from their daily actions to the outcomes that matter.
TRIs Good Clinical Practice e-learning is built on exactly this principle. The programme is CPD-certified and scenario-based, designed so that your trial staff work through the kind of real-world situations they face on study, not abstract theory. Each module connects GCP requirements to the consequences of getting them wrong, which is the mechanism that drives lasting behaviour change. If you are reviewing your training provision in light of ICH E6 (R3) or preparing for a regulatory inspection, explore our GCP e-learning, and see how it maps to your current gaps.
ICH E6 (R3) asks you to think about quality differently. Training is not a starting condition for your trial. It is a continuous quality assurance activity. When you treat it as such, your trial teams make better decisions, your sites generate cleaner data, and the patients who trust you with their safety are better protected.
That is what GCP training is for.